NCT05961696View on ClinicalTrials.gov

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 5, 2023

Primary Completion Date

October 3, 2023

Study Completion Date

October 3, 2023

Conditions
Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Mosunetuzumab

Subcutaneous (SQ or Sub-Q) injection under the skin

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

collaborator

Genentech, Inc.

INDUSTRY